リゲリズマブによる以前の臨床試験を完了した慢性特発性蕁麻疹患者におけるリゲリズマブの有効性および安全性に関する研究

基本情報

NCT ID

NCT04210843

ステータス

中止

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

1,033

治験依頼者名

Novartis

概要

The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1-antihistamine (H1-AH) treatment. This study also fulfilled the Novartis commitment to provide post-trial access to patients who had completed studies: CQGE031C2302 (NCT03580369), CQGE031C2303 (NCT03580356), CQGE031C2202 (NCT03437278) or CQGE031C1301 (NCT03907878).

対象疾患

介入

依頼者（Sponsor）